Statistics for Saroglitazar, a PPAR-α/γ Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double-Blind Phase 2 Trial
Total visits
| views | |
|---|---|
| Saroglitazar, a PPAR-α/γ Agonist, for Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Double-Blind Phase 2 Trial | 119 |
Total visits per month
| views | |
|---|---|
| May 2024 | 0 |
| June 2024 | 1 |
| July 2024 | 0 |
| August 2024 | 0 |
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 0 |
File Visits
| views | |
|---|---|
| Gawrieh2021Saroglitazar-AAM.pdf | 2051 |
Top country views
| views | |
|---|---|
| United States | 81 |
| China | 5 |
| Taiwan | 3 |
| Canada | 2 |
| India | 2 |
| South Korea | 2 |
| Vietnam | 2 |
| Germany | 1 |
| United Kingdom | 1 |
| Greece | 1 |
| Malaysia | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 47 |
| Fairfield | 8 |
| Houston | 7 |
| Ann Arbor | 6 |
| Beijing | 3 |
| Chicago | 3 |
| Dong Ket | 2 |
| Lanham | 2 |
| Taipei | 2 |
| Athens | 1 |
| Cambridge | 1 |
| Gunzenhausen | 1 |
| Kuala Lumpur | 1 |
| Laurel | 1 |
| Mountain View | 1 |
| Nagpur | 1 |
| Ottawa | 1 |
| Shanghai | 1 |
| Toronto | 1 |
| Washington | 1 |
| White Plains | 1 |